|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AC Immune, of Ecublens, Switzerland, completed its Series B financing, raising CHF21 million (US$17.4 million) from private and strategic investors. The company is focused on new therapies to treat Alzheimer's disease using vaccination or passive immunization with antibodies. The financing will take one of AC Immune's three compounds through Phase I development, beginning in 2006.
o Acambis plc, of Cambridge, UK, said Phase I data of its ChimeriVax West Nile vaccine showed that 96 percent of subjects in the high-dose group and 100 percent in the low-dose group developed West Nile-neutralizing antibodies 28 days after vaccination. The trial enrolled 80 subjects. ...